Sugi Predict

Sugi Predict / Compounds / SCHEMBL2390684

SCHEMBL2390684

SCHEMBL2390684

COc1cc(Br)cc(CCC(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 6/20 0.49
▸ THRA P10827 8/20 0.48
▸ THRB P10828 8/20 0.48
▸ FFAR4 Q5NUL3 2/20 0.47
▸ POLB P06746 1/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ NR3C1 P04150 1/20 0.46
▸ PGR P06401 1/20 0.46
▸ NR3C2 P08235 1/20 0.46
▸ AR P10275 1/20 0.46
▸ NFKB1 P19838 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ PPARD Q03181 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15898569 0.90 POLB (0.44) FFAR1THRATHRBFFAR4POLB
SCHEMBL490401 0.88 FFAR1 (0.56) FFAR1THRATHRBFFAR4POLB
SCHEMBL29937542 0.85 KMT2A (0.43) NFKB1NFKB2RELA
SCHEMBL16307105 0.85 KMT2A (0.43) NFKB1NFKB2RELA
SCHEMBL10350883 0.83 PTGS1 (0.51) THRATHRBPOLBNFKB1
SCHEMBL17672986 0.82 KEAP1 (0.52) FFAR1THRATHRBFFAR4ESR1
SCHEMBL23599377 0.81 FFAR1 (0.50) FFAR1THRATHRBFFAR4POLB
SCHEMBL21098761 0.80 FFAR4 (0.51) FFAR1FFAR4POLBNFKB1NFKB2
SCHEMBL7794809 0.78 RXRA (0.54) FFAR1THRATHRBPOLBNFKB1
SCHEMBL227344 0.77 FFAR4 (0.50) FFAR1FFAR4POLBPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
EP-4491622-A2 CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2025-01-15 — — EP disclosed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 — — EP disclosed
CN-117964573-A Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-05-03 — — CN disclosed
CN-117924208-A Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-04-26 — — CN disclosed
CN-113574058-B Indole macrocyclic derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-04-16 — — CN disclosed
CN-111757875-B Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-01-09 — — CN disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-04-28 — — US disclosed
WO-2014201073-A9 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 — — WO disclosed
WO-2014201073-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-18 — — WO disclosed
EP-2042480-B1 AMINOINDAN DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2013-05-01 — — EP disclosed
US-8013018-B2 Aminoindane derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-06 — — US disclosed
US-20090186916-A1 AMINOINDANE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed
EP-2042480-A1 AMINOINDAN DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-01 — — EP disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 — — US disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 — — US disclosed
EP-1795524-A1 CYCLIC AMINE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2007-06-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 FFAR1 2046/4885THRA 1517/4885THRB 1827/4885
US-20090186916-A1 AMINOINDANE DERIVATIVE OR SALT THEREOF GRIN3A, OPRL1, GRIN2A FFAR1 320/4885THRA 2469/4885THRB 1902/4885
US-20070197594-A1 Cyclic amine derivative or salt thereof GRIN1, PARK7, GRIN3A FFAR1 3299/4885THRA 3020/4885THRB 2424/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 FFAR1 4256/4885THRA 3339/4885THRB 1089/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 FFAR1 4256/4885THRA 3339/4885THRB 1089/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS FFAR1 4159/4885THRA 4158/4885THRB 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.